Oncology Expert Insights

Dana M. Chase, MD, discusses the management of recurrent endometrial cancer, emphasizing the importance of biomarker profiles and previous therapies.

Dr Wong discusses the growing challenge of early-onset colorectal cancer and the insights from a recent cohort analysis conducted in Singapore.

Allan and Rubianes discuss factors that influence treatment decision-making for patients with chronic lymphocytic leukemia.

Dr Halmos discusses the VISION trial, the significance of MET exon 14 skipping mutations in NSCLC, and the clinical utility of tepotinib in this disease.

Dr Dorff discusses the role of ADT in prostate cancer management, how this class has evolved, and the use of relugolix across treatment settings.

Drs Logan and Shah discussed where obe-cel currently fits into the B-ALL treatment paradigm and how the use of this agent might expand going forward.

Dr Luke discusses the rationale for evaluating IMA203 in cutaneous melanoma and what the PRAME trial findings may mean for the future of TCR therapy.

Masatoshi Kudo, MD, discusses the evolving treatment landscape in HCC and how recent comparative analyses are helping refine the use of first-line immunotherapy-based regimens.

Drs Kelly and Shiller discuss the importance of performing IHC testing for HER2 in NSCLC and recommendations for IHC testing implementation in practice.

Rocío García-Carbonero, MD, PhD, discusses trends in colorectal cancer and other gastrointestinal malignancies, presented at the 2025 ESMO GI Cancers Congress.

Ignacio Blanco, MD, PhD, discusses the EU marketing authorization of mirdametinib for patients with symptomatic, inoperable plexiform neurofibromas.

Elena Élez, MD, PhD, discusses the evolving role of immunotherapy for patients with microsatellite instability–high metastatic colorectal cancer.

Connie Lai, MD, discusses a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer.

Dr Sabari highlights key research investigating telisotuzumab vedotin in patients with c-Met–overexpressing non–small cell lung cancer.

Xavier Leleu, MD, PhD, and Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO, discuss key data from the phase 3 IRAKLIA study.

Dr Vogel highlights the importance of the European Commission’s approval of zanidatamab for previously treated, metastatic HER2+ biliary tract cancer.

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Justin Moser, MD, discusses the ongoing phase 3 SUPRAME trial investigating IMA203 in previously treated, unresectable or metastatic cutaneous melanoma.

Dr Nagasaka discusses the evolving use of T-DXd for HER2-mutated NSCLC in light of the emergence of investigational agents in this setting.

Dr Dennis discusses guidelines for nasopharyngeal carcinoma management and data with first-line toripalimab plus chemotherapy in metastatic disease.

Kate Gasparini, PharmD, BCOP, BCPPS, discusses the oral formulation of imatinib for pediatric and adult patients with leukemias and other malignancies.

Alicia Morgans, MD, MPH, details the evolving role of AR inhibitors in the mHSPC setting, including the recent expanded approval for darolutamide for this population.

Paolo Tarantino, MD, discusses key updates in HER2-positive breast cancer presented at the 2025 ASCO Annual Meeting

Jonathan W. Goldman, MD, discusses the role of telisotuzumab vedotin in c-MET protein–overexpressing, nonsquamous, EGFR wild-type NSCLC.

Dr Mittendorf shares how ASCO plans to address the implications of federal research funding cuts and how structural reforms may bolster oncology progress.

Dr Mittendorf discusses her priorities for advancing patient care and supporting up-and-coming oncology professionals during her 2026-2027 ASCO presidency.

Dr Kahlon discusses the availability of the generic formulations of eltrombopag for patients with aplastic anemia and immune thrombocytopenia.

Dr Mauro discusses ways that the newest formulation of nilotinib for Ph-positive CML addresses treatment adherence issues by reducing the need for fasting.